Pair Name | Tubeimoside I, TNF-related apoptosis inducing ligand | |||
Partner Name | Tubeimoside I | |||
Disease Info | [ICD-11: 2A00-2F9Z] | Solid tumour or cancer | Investigative | |
Biological Phenomena | Induction-->Apoptosis | |||
Gene Regulation | Down-regulation | Expression | CFLAR | hsa8837 |
Down-regulation | Expression | STAMBPL1 | hsa57559 | |
In Vitro Model | Caki-1 | Clear cell renal cell carcinoma | Homo sapiens (Human) | CVCL_0234 |
A-549 | Lung adenocarcinoma | Homo sapiens (Human) | CVCL_0023 | |
HeLa | Human papillomavirus-related cervical adenocarcinoma | Homo sapiens (Human) | CVCL_0030 | |
HCT 116 | Colon carcinoma | Homo sapiens (Human) | CVCL_0291 | |
In Vivo Model | Male SCID mice were inoculated subcutaneously at the flank with HCT116 (5×10⁶) cells. | |||
Result | Our study revealed that STAMBPL1 is essential for c-FLIP stabilization, and that STAMBPL1 depletion enhances TRAIL-mediated apoptosis via c-FLIP downregulation. |
Pair Name | Thymoquinone, TNF-related apoptosis inducing ligand | |||
Partner Name | Thymoquinone | |||
Disease Info | [ICD-11: 2C60] | Breast cancer | Investigative | |
Biological Phenomena | Induction-->ROS-mediated apoptosis | |||
Gene Regulation | Down-regulation | Expression | BCL2 | hsa596 |
Up-regulation | Expression | CASP8 | hsa841 | |
Up-regulation | Expression | ROS1 | hsa6098 | |
Up-regulation | Expression | TNFRSF10A | hsa8797 | |
Up-regulation | Expression | TNFRSF10B | hsa8795 | |
In Vitro Model | MDA-MB-231 | Breast adenocarcinoma | Homo sapiens (Human) | CVCL_0062 |
MCF-7 | Invasive breast carcinoma of no special type | Homo sapiens (Human) | CVCL_0031 | |
Result | The synergistic influence between TQ which induced the DR5 and TRAIL, facilitating the connection between TRAIL and its receptors on the cancerous cell membrane. Hence, the proposed combination therapy induced the ROS-mediated apoptotic stimulus. |
Pair Name | Tanshinone IIA, TNF-related apoptosis inducing ligand | |||
Partner Name | Tanshinone IIA | |||
Disease Info | [ICD-11: 2A00] | Glioblastoma multiforme | Investigative | |
Biological Phenomena | Induction-->Apoptosis | |||
Gene Regulation | Down-regulation | Phosphorylation | STAT3 | hsa6774 |
Up-regulation | Expression | TNFRSF10A | hsa8797 | |
Up-regulation | Expression | TNFRSF10B | hsa8795 | |
In Vitro Model | U-87MG ATCC | Glioblastoma | Homo sapiens (Human) | CVCL_0022 |
U-251MG | Astrocytoma | Homo sapiens (Human) | CVCL_0021 | |
In Vivo Model | Each mouse was injected subcutaneously with 0.2 mL of U87 cells (1×10⁵ cells/ml) at the hind limb. | |||
Result | T-IIA increases TRAIL-induced apoptosis by downregulating STAT3 and upregulating DR4 and DR5, indicating T-IIA therapy as a novel treatment strategy for TRAIL-resistant GBM. |
Pair Name | Sulforaphane, TNF-related apoptosis inducing ligand | |||
Partner Name | Sulforaphane | |||
Disease Info | [ICD-11: 2C82] | Prostate cancer | Investigative | |
Biological Phenomena | Inhibition-->Angiogenesis | |||
Gene Regulation | Up-regulation | Expression | BAK1 | hsa578 |
Up-regulation | Expression | BAX | hsa581 | |
Down-regulation | Expression | BCL2 | hsa596 | |
Down-regulation | Expression | BCL-xL | hsa598 | |
Up-regulation | Cleavage | CASP3 | hsa836 | |
Down-regulation | Expression | CCNB1 | hsa891 | |
Down-regulation | Expression | CDH13 | hsa1012 | |
Down-regulation | Expression | CDK1 | hsa983 | |
In Vitro Model | PC-3 | Prostate carcinoma | Homo sapiens (Human) | CVCL_0035 |
LNCaP | Prostate carcinoma | Homo sapiens (Human) | CVCL_0395 | |
In Vivo Model | Mice were inoculated with PC-3 cells (1×10⁶ per 100 AL medium) into the dorsolateral lobe of the prostatic capsule. | |||
Result | The ability of sulforaphane to inhibit tumor growth, metastasis, and angiogenesis and to enhance the therapeutic potential of TRAIL suggests that sulforaphane alone or in combination with TRAIL can be used for the management of prostate cancer. |
Pair Name | Shikonin, TNF-related apoptosis inducing ligand | |||
Partner Name | Shikonin | |||
Disease Info | [ICD-11: 2C25] | Lung cancer | Investigative | |
Biological Phenomena | Induction-->Apoptosis | |||
Gene Regulation | Down-regulation | Phosphorylation | AKT1 | hsa207 |
Down-regulation | Expression | BCL2 | hsa596 | |
Down-regulation | Expression | BCL-xL | hsa598 | |
Up-regulation | Expression | BID | hsa637 | |
Down-regulation | Expression | CASP3 | hsa836 | |
Down-regulation | Expression | CASP8 | hsa841 | |
Down-regulation | Expression | CFLAR | hsa8837 | |
Up-regulation | Phosphorylation | MAPK8 | hsa5599 | |
Down-regulation | Expression | MCL1 | hsa4170 | |
Down-regulation | Phosphorylation | STAT3 | hsa6774 | |
Down-regulation | Expression | XIAP | hsa331 | |
In Vitro Model | A-549 | Lung adenocarcinoma | Homo sapiens (Human) | CVCL_0023 |
Result | The results indicated that shikonin sensitized resistant cancer cells to TRAIL-induced cytotoxicity via the modulation of the JNK, STAT3 and AKT pathways, the downregulation of antiapoptotic proteins and the upregulation of proapoptotic proteins. |
Pair Name | Resveratrol, TNF-related apoptosis inducing ligand | |||
Partner Name | Resveratrol | |||
Disease Info | [ICD-11: 2C90.0] | Renal cell carcinoma | Investigative | |
Biological Phenomena | Induction-->Apoptosis | |||
Gene Regulation | Up-regulation | Activity | CASP3 | hsa836 |
Up-regulation | Activity | CASP8 | hsa841 | |
Up-regulation | Activity | CASP9 | hsa842 | |
Down-regulation | Expression | XIAP | hsa331 | |
In Vitro Model | 786-O | Renal cell carcinoma | Homo sapiens (Human) | CVCL_1051 |
OS-RC-2 | Clear cell renal cell carcinoma | Homo sapiens (Human) | CVCL_1626 | |
In Vivo Model | These data demonstrated that RES plus Ad5/35-TRAIL significantly inhibited RCC xenograft growth in nude mice. | |||
Result | Our data demonstrated that RES plus Ad5/35-TRAIL significantly inhibited RCC xenograft growth in nude mice. These results suggest the possibility of a new combination therapeutic leading to the improvement of RCC treatment. |
Pair Name | Pterostilbene, TNF-related apoptosis inducing ligand | |||
Partner Name | Pterostilbene | |||
Disease Info | [ICD-11: 2A00-2F9Z] | Solid tumour or cancer | Investigative | |
Biological Phenomena | Induction-->Apoptosis | |||
Gene Regulation | Down-regulation | Expression | BCL2 | hsa596 |
Down-regulation | Expression | BCL-xL | hsa598 | |
Down-regulation | Expression | BIRC5 | hsa332 | |
Up-regulation | Activity | CASP3 | hsa836 | |
Up-regulation | Activity | CASP8 | hsa841 | |
Up-regulation | Activity | CASP9 | hsa842 | |
Up-regulation | Activity | DDIT3 | hsa1649 | |
Up-regulation | Cleavage | PARP1 | hsa142 | |
Up-regulation | Expression | TNFRSF10A | hsa8797 | |
Up-regulation | Expression | TNFRSF10B | hsa8795 | |
Down-regulation | Expression | XIAP | hsa331 | |
In Vitro Model | BT-20 | Invasive breast carcinoma | Homo sapiens (Human) | CVCL_0178 |
Result | Pterostilbene enhances TRAIL-induced apoptosis through the induction of death receptors and downregulation of cell survival proteins in TRAIL-resistance triple negative breast cancer cells |
Pair Name | Periplocin, TNF-related apoptosis inducing ligand | |||
Partner Name | Periplocin | |||
Disease Info | [ICD-11: 2B70.1] | Esophageal squamous cell carcinoma | Investigative | |
Biological Phenomena | Induction-->Apoptosis | |||
Gene Regulation | Down-regulation | Expression | BIRC5 | hsa332 |
Up-regulation | Cleavage | CASP3 | hsa836 | |
Up-regulation | Cleavage | CASP8 | hsa841 | |
Down-regulation | Activity | CTNNB1 | hsa1499 | |
Down-regulation | Phosphorylation | CTNNB1 | hsa1499 | |
Down-regulation | Activity | FOXP3 | hsa50943 | |
Up-regulation | Expression | TNFRSF10A | hsa8797 | |
Up-regulation | Expression | TNFRSF10B | hsa8795 | |
In Vitro Model | Eca-109 | Esophageal squamous cell carcinoma | Homo sapiens (Human) | CVCL_6898 |
TE-1 | Esophageal squamous cell carcinoma | Homo sapiens (Human) | CVCL_1759 | |
YES-2 | Esophageal squamous cell carcinoma | Homo sapiens (Human) | CVCL_E322 | |
KYSE-30 | Esophageal squamous cell carcinoma | Homo sapiens (Human) | CVCL_1351 | |
KYSE-410 | Esophageal squamous cell carcinoma | Homo sapiens (Human) | CVCL_1352 | |
KYSE-510 | Esophageal squamous cell carcinoma | Homo sapiens (Human) | CVCL_1354 | |
Result | Our data suggest that CPP and TRAIL could be further explored as potential therapeutic approach for esophageal cancer. |
Pair Name | Periplocin, TNF-related apoptosis inducing ligand | |||
Partner Name | Periplocin | |||
Disease Info | [ICD-11: 2B72] | Gastric cancer | Investigative | |
Biological Phenomena | Induction-->Apoptosis | |||
Gene Regulation | Down-regulation | Expression | BCL2 | hsa596 |
Down-regulation | Expression | BID | hsa637 | |
Up-regulation | Cleavage | CASP3 | hsa836 | |
Up-regulation | Expression | CASP8 | hsa841 | |
Up-regulation | Expression | EGR1 | hsa1958 | |
Up-regulation | Phosphorylation | MAPK1 | hsa5594 | |
Down-regulation | Expression | MCL1 | hsa4170 | |
Up-regulation | Expression | TNFRSF10A | hsa8797 | |
Up-regulation | Expression | TNFRSF10B | hsa8795 | |
In Vivo Model | The proceduresusing animals were approved by the Animal Care and Use Committee.SGC-7901 cells (1×10⁵/100μL/mouse) were suspended in 0.9%physiological saline and subcutaneously injected into the right flank ofeach mouse. | |||
Result | Antitumor Effect of Periplocin in TRAIL-Resistant gastric cancer cells via upregulation of death receptor through activating ERK1/2-EGR1 pathway |
Pair Name | Neobavaisoflavone, TNF-related apoptosis inducing ligand | |||
Partner Name | Neobavaisoflavone | |||
Disease Info | [ICD-11: 2F7Z] | Glioma | Investigative | |
Biological Phenomena | Induction-->Apoptosis | |||
Gene Regulation | Up-regulation | Expression | BAX | hsa581 |
Up-regulation | Cleavage | BID | hsa637 | |
Up-regulation | Activity | CASP3 | hsa836 | |
Up-regulation | Activity | CASP8 | hsa841 | |
Up-regulation | Activity | CASP9 | hsa842 | |
Up-regulation | Expression | TNFRSF10B | hsa8795 | |
In Vitro Model | U-373MG ATCC | Astrocytoma | Homo sapiens (Human) | CVCL_2219 |
Result | Taken together, our results suggest that NBIF reduces the resistance of cancer cells to TRAIL and that the combination of NBIF and TRAIL may be a new therapeutic strategy for treating TRAIL-resistant glioma cells. |
Pair Name | Medicarpin, TNF-related apoptosis inducing ligand | |||
Partner Name | Medicarpin | |||
Disease Info | [ICD-11: 2B33.1] | Myeloid leukemia | Investigative | |
Biological Phenomena | Induction-->Blockade of cell cycle in G2/M phase | |||
Gene Regulation | Up-regulation | Expression | BAX | hsa581 |
Down-regulation | Expression | BCL2 | hsa596 | |
Down-regulation | Expression | BCL-xL | hsa598 | |
Up-regulation | Expression | BID | hsa637 | |
Down-regulation | Expression | BIRC5 | hsa332 | |
Up-regulation | Cleavage | CASP3 | hsa836 | |
Up-regulation | Cleavage | CASP7 | hsa840 | |
Up-regulation | Cleavage | CASP8 | hsa841 | |
Up-regulation | Cleavage | CASP9 | hsa842 | |
Down-regulation | Expression | CFLAR | hsa8837 | |
Up-regulation | Expression | CYCS | hsa54205 | |
Up-regulation | Expression | DDIT3 | hsa1649 | |
Up-regulation | Expression | DIABLO | hsa56616 | |
Down-regulation | Expression | DIABLO | hsa56616 | |
Up-regulation | Phosphorylation | EIF2S1 | hsa1965 | |
Up-regulation | Expression | HSPA5 | hsa3309 | |
Up-regulation | Phosphorylation | MAPK8 | hsa5599 | |
Up-regulation | Expression | TNFRSF10B | hsa8795 | |
Down-regulation | Expression | XIAP | hsa331 | |
In Vitro Model | K-562 | Blast phase chronic myelogenous leukemia | Homo sapiens (Human) | CVCL_0004 |
LAMA-84 | Chronic myelogenous leukemia | Homo sapiens (Human) | CVCL_0388 | |
U-937 | Adult acute monocytic leukemia | Homo sapiens (Human) | CVCL_0007 | |
OCI-AML-3 | Adult acute myeloid leukemia | Homo sapiens (Human) | CVCL_1844 | |
Result | Medicarpin, a legume phytoalexin sensitizes myeloid leukemia cells to TRAIL-induced apoptosis through the induction of DR5 and activation of the ROS-JNK-CHOP pathway |
Pair Name | Luteolin, TNF-related apoptosis inducing ligand | |||
Partner Name | Luteolin | |||
Disease Info | [ICD-11: 2C25] | Lung cancer | Investigative | |
Biological Phenomena | Induction-->Mitochondrial fission and apoptosis | |||
Gene Regulation | Up-regulation | Expression | DNM1L | hsa10059 |
Up-regulation | Phosphorylation | MAPK8 | hsa5599 | |
Up-regulation | Expression | TNFRSF10B | hsa8795 | |
In Vitro Model | A-549 | Lung adenocarcinoma | Homo sapiens (Human) | CVCL_0023 |
NCI-H1975 | Lung adenocarcinoma | Homo sapiens (Human) | CVCL_1511 | |
Result | TRAIL combined with luteolin could be as an effective chemotherapeutic strategy for NSCLC. |
Pair Name | Luteolin, TNF-related apoptosis inducing ligand | |||
Partner Name | Luteolin | |||
Disease Info | [ICD-11: 2C25] | Lung cancer | Investigative | |
Biological Phenomena | Induction-->Apoptosis | |||
Gene Regulation | Up-regulation | Cleavage | CASP8 | hsa841 |
Up-regulation | Cleavage | CASP9 | hsa842 | |
Up-regulation | Cleavage | PARP1 | hsa142 | |
In Vitro Model | A-549 | Lung adenocarcinoma | Homo sapiens (Human) | CVCL_0023 |
In Vivo Model | A549 non-small cell lung cancer cells (2×10⁶) resuspended in 0.1mL of PBS were injected subcutaneously into athymic (nu/nu) male nude mice (5-6 weeks old). | |||
Result | Data from this study thus provide strong in vivo evidence supporting that luteolin is a potential sensitizer for TRAIL in anticancer therapy. |
Pair Name | Luteolin, TNF-related apoptosis inducing ligand | |||
Partner Name | Luteolin | |||
Disease Info | [ICD-11: 2C10] | Pancreatic cancer | Investigative | |
Gene Regulation | Down-regulation | Expression | CASP8 | hsa841 |
Down-regulation | Expression | MIR301A | hsa407027 | |
In Vitro Model | PANC-1 | Pancreatic ductal adenocarcinoma | Homo sapiens (Human) | CVCL_0480 |
Result | Our findings unveil a critical biological function of miR-301-3p in regulating cell proliferation and elevating an antiproliferative effect of TRAIL on cancer cells. Our observation of miR-301-3p/caspase-8 relationship can also serve to clarify the role of miR-301-3p in other cancer types and related diseases. |
Pair Name | Liquiritin, TNF-related apoptosis inducing ligand | |||
Partner Name | Liquiritin | |||
Disease Info | [ICD-11: 2B72] | Gastric cancer | Investigative | |
Biological Phenomena | Induction-->ROS generation | |||
Gene Regulation | Up-regulation | Expression | BAX | hsa581 |
Down-regulation | Expression | BCL2 | hsa596 | |
Up-regulation | Cleavage | CASP3 | hsa836 | |
Up-regulation | Cleavage | CASP8 | hsa841 | |
Up-regulation | Cleavage | CASP9 | hsa842 | |
Up-regulation | Expression | CDH1 | hsa999 | |
Down-regulation | Expression | CDH2 | hsa1000 | |
Up-regulation | Expression | FADD | hsa8772 | |
Up-regulation | Phosphorylation | MAPK8 | hsa5599 | |
Up-regulation | Cleavage | PARP1 | hsa142 | |
Up-regulation | Expression | TNFRSF10A | hsa8797 | |
Up-regulation | Expression | TNFRSF10B | hsa8795 | |
Down-regulation | Expression | TWIST1 | hsa7291 | |
Down-regulation | Expression | VIM | hsa7431 | |
In Vitro Model | AGS | Gastric adenocarcinoma | Homo sapiens (Human) | CVCL_0139 |
SNU-216 | Gastric tubular adenocarcinoma | Homo sapiens (Human) | CVCL_3946 | |
Result | Combining TRAIL and liquiritin exerts synergistic effects against human gastric cancer cells and xenograft in nude mice through potentiating apoptosis and ROS generation |
Pair Name | Licochalcone B, TNF-related apoptosis inducing ligand | |||
Partner Name | Licochalcone B | |||
Disease Info | [ICD-11: 2C12] | Hepatocellular carcinoma | Investigative | |
Biological Phenomena | Induction-->Apoptosis | |||
Gene Regulation | Down-regulation | Phosphorylation | AKT1 | hsa207 |
Up-regulation | Phosphorylation | ATM | hsa472 | |
Up-regulation | Cleavage | CASP8 | hsa841 | |
Down-regulation | Expression | CCNB1 | hsa891 | |
Down-regulation | Expression | CCND1 | hsa595 | |
Down-regulation | Phosphorylation | CDK1 | hsa983 | |
Down-regulation | Expression | CDK1 | hsa983 | |
Up-regulation | Phosphorylation | CHEK2 | hsa11200 | |
Up-regulation | Expression | DDIT3 | hsa1649 | |
Down-regulation | Expression | EIF2AK3 | hsa9451 | |
Up-regulation | Expression | H2AX | hsa3014 | |
Up-regulation | Expression | HSPA5 | hsa3309 | |
Up-regulation | Phosphorylation | MAPK1 | hsa5594 | |
Up-regulation | Phosphorylation | MAPK14 | hsa1432 | |
Up-regulation | Phosphorylation | MAPK3 | hsa5595 | |
Up-regulation | Phosphorylation | MAPK8 | hsa5599 | |
Up-regulation | Phosphorylation | MAPK9 | hsa5601 | |
Up-regulation | Cleavage | PARP1 | hsa142 | |
Up-regulation | Cleavage | PARP1 | hsa142 | |
Up-regulation | Expression | PSMD9 | hsa5715 | |
Down-regulation | Phosphorylation | RPS6KB1 | hsa6198 | |
Up-regulation | Expression | TNFRSF10A | hsa8797 | |
Up-regulation | Expression | TNFRSF10B | hsa8795 | |
Result | LCB exhibits cytotoxic activity through modulation of the Akt/mTOR, ER stress and MAPK pathways in HCC cells and effectively enhances TRAIL sensitivity through the upregulation of DR5 expression in ERK- and JNK-dependent manner. Combination therapy with LCB and TRAIL may be an alternative treatment strategy for HCC. |
Pair Name | Kurarinone, TNF-related apoptosis inducing ligand | |||
Partner Name | Kurarinone | |||
Disease Info | [ICD-11: 2B72] | Gastric cancer | Investigative | |
Biological Phenomena | Induction-->Blockade of cell cycle in G2/M phase | |||
Gene Regulation | Up-regulation | Cleavage | CASP3 | hsa836 |
Down-regulation | Expression | CCNA2 | hsa890 | |
Down-regulation | Expression | CCNB1 | hsa891 | |
Down-regulation | Expression | CFLAR | hsa8837 | |
Down-regulation | Expression | MCL1 | hsa4170 | |
Up-regulation | Cleavage | PARP1 | hsa142 | |
Down-regulation | Expression | STAT3 | hsa6774 | |
In Vitro Model | SGC-7901 | Human papillomavirus-related cervical adenocarcinoma | Homo sapiens (Human) | CVCL_0520 |
Result | Kurarinone Synergizes TRAIL-Induced Apoptosis in Gastric Cancer Cells |
Pair Name | Kaempferol, TNF-related apoptosis inducing ligand | |||
Partner Name | Kaempferol | |||
Disease Info | [ICD-11: 2B90] | Colon cancer | Investigative | |
Biological Phenomena | Induction-->Apoptosis | |||
Gene Regulation | Up-regulation | Expression | TNFRSF10A | hsa8797 |
Up-regulation | Expression | TNFRSF10B | hsa8795 | |
In Vitro Model | SW480 | Colon adenocarcinoma | Homo sapiens (Human) | CVCL_0546 |
Result | The co-treatment induced no apoptosis in normal human peripheral blood mononuclear cells and little apoptosis in normal human hepatocytes. These results suggest that kaempferol is useful for TRAIL-based treatments for cancer. |
Pair Name | Kaempferol, TNF-related apoptosis inducing ligand | |||
Partner Name | Kaempferol | |||
Disease Info | [ICD-11: 2A20.1] | Chronic myelogenous leukemia | Investigative | |
Biological Phenomena | Induction-->Apoptosis | |||
Gene Regulation | Down-regulation | Expression | BIRC2 | hsa329 |
Down-regulation | Expression | BIRC3 | hsa330 | |
Down-regulation | Expression | CFLAR | hsa8837 | |
Up-regulation | Expression | TNFRSF10A | hsa8797 | |
Up-regulation | Expression | TNFRSF10B | hsa8795 | |
In Vitro Model | K-562 | Blast phase chronic myelogenous leukemia | Homo sapiens (Human) | CVCL_0004 |
Result | It is reasonable to conclude that sensitization of chronic leukemia cells to TRAIL by kaempferol in vitro should be considered as a way of focusing clinical attention on leukemia therapy. |
Pair Name | Isoquercitrin, TNF-related apoptosis inducing ligand | |||
Partner Name | Isoquercitrin | |||
Disease Info | [ICD-11: 2C77] | Cervical cancer | Investigative | |
Biological Phenomena | Induction-->Apoptosis | |||
Gene Regulation | Up-regulation | Expression | TNFRSF10A | hsa8797 |
Up-regulation | Expression | TNFRSF10B | hsa8795 | |
In Vitro Model | SiHa | Human papillomavirus-related cervical squamous cell carcinoma | Homo sapiens (Human) | CVCL_0032 |
Result | We found that isoquercitrin enhances the mRNA expression of TRAIL-Rs, but the percentage of apoptosis was meager, possibly due to the influence of other anti-apoptotic proteins. |
Pair Name | Isoliquiritigenin, TNF-related apoptosis inducing ligand | |||
Partner Name | Isoliquiritigenin | |||
Disease Info | [ICD-11: 2B90] | Colon cancer | Investigative | |
Biological Phenomena | Induction-->Apoptosis and autophagy | |||
Gene Regulation | Up-regulation | Expression | BAX | hsa581 |
Down-regulation | Expression | BCL2 | hsa596 | |
Down-regulation | Expression | BCL-xL | hsa598 | |
Up-regulation | Expression | TNFRSF10B | hsa8795 | |
In Vitro Model | HT-29 | Colon adenocarcinoma | Homo sapiens (Human) | CVCL_0320 |
Result | Isoliquiritigenin has the potential to overcome resistance to TRAIL in cancer cells and its chemopreventive effects may depend on TRAIL function |
Pair Name | Irigenin, TNF-related apoptosis inducing ligand | |||
Partner Name | Irigenin | |||
Disease Info | [ICD-11: 2B72] | Gastric cancer | Investigative | |
Biological Phenomena | Induction-->Apoptosis | |||
Gene Regulation | Up-regulation | Expression | BAX | hsa581 |
Down-regulation | Expression | BCL2 | hsa596 | |
Up-regulation | Cleavage | CASP3 | hsa836 | |
Up-regulation | Cleavage | CASP8 | hsa841 | |
Up-regulation | Cleavage | CASP9 | hsa842 | |
Down-regulation | Expression | CFLAR | hsa8837 | |
Up-regulation | Expression | FADD | hsa8772 | |
Up-regulation | Cleavage | PARP1 | hsa142 | |
Up-regulation | Expression | TNFRSF10B | hsa8795 | |
In Vitro Model | NCI-N87 | Gastric tubular adenocarcinoma | Homo sapiens (Human) | CVCL_1603 |
SGC-7901 | Human papillomavirus-related cervical adenocarcinoma | Homo sapiens (Human) | CVCL_0520 | |
BGC-823 | Human papillomavirus-related cervical adenocarcinoma | Homo sapiens (Human) | CVCL_3360 | |
MGC-803 | Gastric mucinous adenocarcinoma | Homo sapiens (Human) | CVCL_5334 | |
MKN28 | Gastric tubular adenocarcinoma | Homo sapiens (Human) | CVCL_1416 | |
Result | Our present study gave new insights into the effects of Iri on potentiating TRAIL-sensitivity, and suggested that Iri could be a potential candidate for sensitizer of TRAIL-resistant cancer cell treatment. |
Pair Name | Icaritin, TNF-related apoptosis inducing ligand | |||
Partner Name | Icaritin | |||
Disease Info | [ICD-11: 2A00] | Glioblastoma multiforme | Investigative | |
Biological Phenomena | Induction-->Apoptosis | |||
Gene Regulation | Up-regulation | Cleavage | CASP3 | hsa836 |
Down-regulation | Expression | CFLAR | hsa8837 | |
Up-regulation | Cleavage | PARP1 | hsa142 | |
Down-regulation | Expression | RELA | hsa5970 | |
In Vitro Model | U-373MG ATCC | Astrocytoma | Homo sapiens (Human) | CVCL_2219 |
U-87MG ATCC | Glioblastoma | Homo sapiens (Human) | CVCL_0022 | |
Result | These data suggest that icaritin sensitizes TRAIL-induced tumor cell apoptosis via suppression of NF-κB-dependent c-FLIP expression, providing in vitro evidence supporting the notion that icaritin is a potential sensitizer of TRAIL in anticancer therapy against human GBM. |
Pair Name | Gomisin N, TNF-related apoptosis inducing ligand | |||
Partner Name | Gomisin N | |||
Disease Info | [ICD-11: 2C77] | Cervical cancer | Investigative | |
Biological Phenomena | Induction-->Apoptosis | |||
Gene Regulation | Up-regulation | Expression | ROS1 | hsa6098 |
Up-regulation | Expression | TNFRSF10A | hsa8797 | |
Up-regulation | Expression | TNFRSF10B | hsa8795 | |
In Vitro Model | HeLa | Human papillomavirus-related cervical adenocarcinoma | Homo sapiens (Human) | CVCL_0030 |
Result | Our results indicated that gomisin N was able to potentiate TRAIL-induced apoptosis through ROS-mediated up-regulation of DR4 and DR5. |
Pair Name | Gambogic Acid, TNF-related apoptosis inducing ligand | |||
Partner Name | Gambogic Acid | |||
Disease Info | [ICD-11: 2C60] | Breast cancer | Investigative | |
Biological Phenomena | Induction-->Apoptosis | |||
Gene Regulation | Down-regulation | Expression | BCL2 | hsa596 |
Down-regulation | Expression | BCL-xL | hsa598 | |
Down-regulation | Expression | BID | hsa637 | |
Down-regulation | Expression | BIRC5 | hsa332 | |
Up-regulation | Cleavage | CASP3 | hsa836 | |
Up-regulation | Cleavage | CASP7 | hsa840 | |
Up-regulation | Cleavage | CASP8 | hsa841 | |
Down-regulation | Cleavage | PARP1 | hsa142 | |
Up-regulation | Expression | XIAP | hsa331 | |
In Vitro Model | MCF-7 | Invasive breast carcinoma of no special type | Homo sapiens (Human) | CVCL_0031 |
MDA-MB-231 | Breast adenocarcinoma | Homo sapiens (Human) | CVCL_0062 | |
Result | These findings may open a new window in the treatment of breast cancer using TRAIL in combination with GA. |
Pair Name | Fucoxanthin, TNF-related apoptosis inducing ligand | |||
Partner Name | Fucoxanthin | |||
Disease Info | [ICD-11: 2C77] | Cervical cancer | Investigative | |
Gene Regulation | Down-regulation | Phosphorylation | AKT1 | hsa207 |
Down-regulation | Phosphorylation | PIK3CA | hsa5290 | |
In Vitro Model | Ca Ski | Human papillomavirus-related cervical squamous cell carcinoma | Homo sapiens (Human) | CVCL_1100 |
In Vivo Model | Five-week-old nude BALB/c mice were used for subcutaneous implantation of human cervical tumor cells HeLa (2×10⁶ per site). | |||
Result | The findings of this study suggest that the combined use of fucoxanthin and TRAIL might be a useful strategy against TRAIL-resistant cervical cancer. |
Pair Name | Fucoxanthin, TNF-related apoptosis inducing ligand | |||
Partner Name | Fucoxanthin | |||
Disease Info | [ICD-11: 2C77] | Cervical cancer | Investigative | |
Biological Phenomena | Induction-->Apoptosis | |||
Gene Regulation | Down-regulation | Phosphorylation | AKT1 | hsa207 |
Up-regulation | Expression | BAX | hsa581 | |
Down-regulation | Expression | BCL2 | hsa596 | |
Up-regulation | Cleavage | CASP3 | hsa836 | |
Down-regulation | Expression | RELA | hsa5970 | |
In Vitro Model | HeLa | Human papillomavirus-related cervical adenocarcinoma | Homo sapiens (Human) | CVCL_0030 |
SiHa | Human papillomavirus-related cervical squamous cell carcinoma | Homo sapiens (Human) | CVCL_0032 | |
Ca Ski | Human papillomavirus-related cervical squamous cell carcinoma | Homo sapiens (Human) | CVCL_1100 | |
Result | We found that fucoxanthin- or TRAIL-induced apoptosis of human cervical cancer cells was obviously down-regulated. CONCLUSIONS Taken together, these findings suggest that fucoxanthin and TRAIL increased the apoptosis in human cervical cancer cells by targeting the PI3K/Akt/NF-κB signaling pathway. |
Pair Name | Epigallocatechin gallate, TNF-related apoptosis inducing ligand | |||
Partner Name | Epigallocatechin gallate | |||
Disease Info | [ICD-11: 2B90] | Colon cancer | Investigative | |
Biological Phenomena | Induction-->Autophagy | |||
Gene Regulation | Down-regulation | Expression | TNFRSF10B | hsa8795 |
In Vitro Model | HCT 116 | Colon carcinoma | Homo sapiens (Human) | CVCL_0291 |
Result | Activation of autophagic flux by epigallocatechin gallate mitigates TRAIL-induced tumor cell apoptosis via down-regulation of death receptors |
Pair Name | Epigallocatechin gallate, TNF-related apoptosis inducing ligand | |||
Partner Name | Epigallocatechin gallate | |||
Disease Info | [ICD-11: 2A00] | Glioblastoma multiforme | Investigative | |
Biological Phenomena | Induction-->Apoptosis | |||
Gene Regulation | Down-regulation | Expression | PEA15 | hsa8682 |
In Vitro Model | U-87MG ATCC | Glioblastoma | Homo sapiens (Human) | CVCL_0022 |
A-172 | Glioblastoma | Homo sapiens (Human) | CVCL_0131 | |
U-251MG | Astrocytoma | Homo sapiens (Human) | CVCL_0021 | |
Result | Epigalocatechin-3-gallate (EGCG) downregulates PEA15 and thereby augments TRAIL-mediated apoptosis in malignant glioma |
Pair Name | Epigallocatechin gallate, TNF-related apoptosis inducing ligand | |||
Partner Name | Epigallocatechin gallate | |||
Disease Info | [ICD-11: 2C30] | Melanoma | Investigative | |
Biological Phenomena | Induction-->Apoptosis | |||
Gene Regulation | Up-regulation | Activity | CASP3 | hsa836 |
Up-regulation | Expression | TNFRSF10A | hsa8797 | |
In Vitro Model | A-375 | Amelanotic melanoma | Homo sapiens (Human) | CVCL_0132 |
Result | EGCG enhances TRAIL-mediated apoptosis in human melanoma A375 cell line |
Pair Name | Epigallocatechin gallate, TNF-related apoptosis inducing ligand | |||
Partner Name | Epigallocatechin gallate | |||
Disease Info | [ICD-11: 2C10] | Pancreatic cancer | Investigative | |
Biological Phenomena | Induction-->Apoptosis | |||
Gene Regulation | Up-regulation | Cleavage | CASP3 | hsa836 |
In Vitro Model | MIA PaCa-2 | Pancreatic ductal adenocarcinoma | Homo sapiens (Human) | CVCL_0428 |
Result | Combination of epigallocatechin-3-gallate and TRAIL synergistically increase the apoptosis and cleavage of procaspase-3 in pancreatic cancer cells |
Pair Name | Epigallocatechin gallate, TNF-related apoptosis inducing ligand | |||
Partner Name | Epigallocatechin gallate | |||
Disease Info | [ICD-11: 2B6B] | Nasopharyngeal carcinoma | Investigative | |
Biological Phenomena | Induction-->Apoptosis | |||
Gene Regulation | Down-regulation | Expression | BCL2 | hsa596 |
Down-regulation | Expression | BCL-xL | hsa598 | |
Down-regulation | Expression | BIRC5 | hsa332 | |
Up-regulation | Activity | CASP3 | hsa836 | |
Up-regulation | Activity | CASP8 | hsa841 | |
Up-regulation | Activity | CASP9 | hsa842 | |
Down-regulation | Expression | CDH13 | hsa1012 | |
Down-regulation | Expression | CFLAR | hsa8837 | |
Down-regulation | Expression | FADD | hsa8772 | |
Down-regulation | Expression | XIAP | hsa331 | |
In Vitro Model | CNE-1 | Nasopharyngeal carcinoma | Homo sapiens (Human) | CVCL_6888 |
CNE-2 | Nasopharyngeal carcinoma | Homo sapiens (Human) | CVCL_6889 | |
C666-1 | Nasopharyngeal carcinoma | Homo sapiens (Human) | CVCL_7949 | |
NP69SV40T | Healthy | Homo sapiens (Human) | CVCL_F755 | |
Result | EGCG sensitizes NPC cells to TRAIL-mediated apoptosis via modulation of extrinsic and intrinsic apoptotic pathways and inhibition of NF-κB activation. |
Pair Name | Epigallocatechin gallate, TNF-related apoptosis inducing ligand | |||
Partner Name | Epigallocatechin gallate | |||
Disease Info | [ICD-11: 2C82] | Prostate cancer | Investigative | |
Biological Phenomena | Induction-->Apoptosis | |||
Gene Regulation | Down-regulation | Expression | ANGPT1 | hsa284 |
Down-regulation | Expression | BAD | hsa572 | |
Up-regulation | Expression | BAX | hsa581 | |
Down-regulation | Expression | BCL2 | hsa596 | |
Down-regulation | Expression | BIRC3 | hsa330 | |
Down-regulation | Expression | BIRC5 | hsa332 | |
Down-regulation | Expression | CASP3 | hsa836 | |
Down-regulation | Expression | CASP6 | hsa839 | |
Down-regulation | Expression | CASP8 | hsa841 | |
Down-regulation | Expression | CASP9 | hsa842 | |
Down-regulation | Expression | MMP2 | hsa4313 | |
Down-regulation | Expression | MMP3 | hsa4314 | |
Down-regulation | Expression | MMP9 | hsa4318 | |
Up-regulation | Cleavage | PARP1 | hsa142 | |
Down-regulation | Expression | PARP1 | hsa142 | |
Up-regulation | Expression | TIMP1 | hsa7076 | |
Down-regulation | Expression | VEGFA | hsa7422 | |
Down-regulation | Expression | XIAP | hsa331 | |
In Vitro Model | LNCaP | Prostate carcinoma | Homo sapiens (Human) | CVCL_0395 |
Result | EGCG sensitizes human prostate carcinoma LNCaP cells to TRAIL-mediated apoptosis and synergistically inhibits biomarkers associated with angiogenesis and metastasis |
Pair Name | Decursin, TNF-related apoptosis inducing ligand | |||
Partner Name | Decursin | |||
Disease Info | [ICD-11: 2C25] | Lung cancer | Investigative | |
Biological Phenomena | Induction-->Endoplasmic reticulum stress | |||
Gene Regulation | Up-regulation | Activity | ATF4 | hsa468 |
Up-regulation | Expression | DDIT3 | hsa1649 | |
Up-regulation | Activity | EIF2AK3 | hsa9451 | |
Up-regulation | Expression | ROS1 | hsa6098 | |
Up-regulation | Expression | TNFRSF10B | hsa8795 | |
In Vitro Model | A-549 | Lung adenocarcinoma | Homo sapiens (Human) | CVCL_0023 |
NCI-H596 | Lung adenosquamous carcinoma | Homo sapiens (Human) | CVCL_1571 | |
NCI-H1299 | Lung large cell carcinoma | Homo sapiens (Human) | CVCL_0060 | |
Calu-1 | Lung squamous cell carcinoma | Homo sapiens (Human) | CVCL_0608 | |
Result | ROS generation by decursin selectively activated the PERK/ATF4 axis of the endoplasmic reticulum stress signalling pathway, leading to enhanced TRAIL sensitivity in TRAIL-resistant NSCLC cell lines, partly via up-regulation of DR5. |
Pair Name | Curcumin, TNF-related apoptosis inducing ligand | |||
Partner Name | Curcumin | |||
Disease Info | [ICD-11: 2C17] | Hepatocellular carcinoma | Investigative | |
Biological Phenomena | Induction-->Oxidative Stress-dependent apoptosis | |||
Gene Regulation | Down-regulation | Expression | BIRC2 | hsa329 |
Up-regulation | Cleavage | CASP8 | hsa841 | |
Down-regulation | Expression | CCR6 | hsa1235 | |
Down-regulation | Expression | DDX3X | hsa1654 | |
Down-regulation | Expression | GSK3B | hsa2932 | |
Up-regulation | Expression | TNFRSF10B | hsa8795 | |
In Vitro Model | HuCCA-1 | Intrahepatic cholangiocarcinoma | Homo sapiens (Human) | CVCL_M255 |
KKU-213A | Intrahepatic cholangiocarcinoma | Homo sapiens (Human) | CVCL_M261 | |
Result | The present study demonstrates the potential of using curcumin in combination with TRAIL to yield better TRAIL therapy outcomes in TRAIL-resistant CCA. |
Pair Name | Curcumin, TNF-related apoptosis inducing ligand | |||
Partner Name | Curcumin | |||
Disease Info | [ICD-11: 2C25] | Lung cancer | Investigative | |
Biological Phenomena | Induction-->Apoptosis | |||
Gene Regulation | Down-regulation | Phosphorylation | AKT1 | hsa207 |
Up-regulation | Expression | BAX | hsa581 | |
Down-regulation | Expression | BCL2 | hsa596 | |
Up-regulation | Cleavage | CASP3 | hsa836 | |
Up-regulation | Cleavage | CASP9 | hsa842 | |
Down-regulation | Expression | CDH13 | hsa1012 | |
Up-regulation | Expression | CDKN1A | hsa1026 | |
Up-regulation | Phosphorylation | MAPK1 | hsa5594 | |
Up-regulation | Phosphorylation | MAPK3 | hsa5595 | |
Down-regulation | Expression | MMP2 | hsa4313 | |
Down-regulation | Expression | MMP9 | hsa4318 | |
Down-regulation | Activity | NFKB1 | hsa4790 | |
Up-regulation | Expression | TP53 | hsa7157 | |
In Vitro Model | A-549 | Lung adenocarcinoma | Homo sapiens (Human) | CVCL_0023 |
Result | Combined treatment with curcumin and carboplatin inhibited tumor cell growth, migration, and invasion compared with either drug alone. The synergistic antitumor activity of curcumin combined with carboplatin is mediated by multiple mechanisms involving suppression of NF-kappaB via inhibition of the Akt/IKKalpha pathway and enhanced ERK1/2 activity |
Pair Name | Chicoric acid, TNF-related apoptosis inducing ligand | |||
Partner Name | Chicoric acid | |||
Disease Info | [ICD-11: 2C12] | Hepatocellular carcinoma | Investigative | |
Biological Phenomena | Induction-->Apoptosis | |||
Gene Regulation | Up-regulation | Activity | CASP3 | hsa836 |
Down-regulation | Expression | MAP2K7 | hsa5609 | |
Up-regulation | Activity | MAPK8 | hsa5599 | |
Down-regulation | Expression | TIPRL | hsa261726 | |
In Vitro Model | Huh-7 | Adult hepatocellular carcinoma | Homo sapiens (Human) | CVCL_0336 |
Result | Our results suggest that TO plays an important role in TRAIL-induced apoptosis, and further functional studies are warranted to confirm the importance of TO as a novel TRAIL sensitizer for cancer therapy. |
Pair Name | Celastrol, TNF-related apoptosis inducing ligand | |||
Partner Name | Celastrol | |||
Disease Info | [ICD-11: 2A00] | Glioblastoma multiforme | Investigative | |
Biological Phenomena | Induction-->Apoptosis | |||
Gene Regulation | Up-regulation | Cleavage | CASP3 | hsa836 |
Up-regulation | Cleavage | CASP8 | hsa841 | |
Up-regulation | Cleavage | PARP1 | hsa142 | |
In Vitro Model | U-87MG ATCC | Glioblastoma | Homo sapiens (Human) | CVCL_0022 |
U-251MG | Astrocytoma | Homo sapiens (Human) | CVCL_0021 | |
LN-229 | Glioblastoma | Homo sapiens (Human) | CVCL_0393 | |
Result | The results of our study demonstrate that celastrol sensitizes glioma cells to TRAIL via the death receptor pathway and that DR5 plays an important role in the effects of this cotreatment. The results indicate that this cotreatment is a promising tumor-killing therapeutic strategy with high efficacy and low toxicity. |
Pair Name | Celastrol, TNF-related apoptosis inducing ligand | |||
Partner Name | Celastrol | |||
Disease Info | [ICD-11: 2C25] | Lung cancer | Investigative | |
Biological Phenomena | Induction-->Apoptosis | |||
Gene Regulation | Up-regulation | Activity | CASP3 | hsa836 |
Up-regulation | Activity | CASP8 | hsa841 | |
Up-regulation | Expression | MAP1LC3A | hsa84557 | |
Up-regulation | Expression | SQSTM1 | hsa8878 | |
In Vitro Model | A-549 | Lung adenocarcinoma | Homo sapiens (Human) | CVCL_0023 |
HCC15 | Lung squamous cell carcinoma | Homo sapiens (Human) | CVCL_2057 | |
Calu-3 | Lung adenocarcinoma | Homo sapiens (Human) | CVCL_0609 | |
Result | The combined use of TRAIL with celastrol may serve as a safe and adequate therapeutic technique for the treatment of TRAIL‑resistant lung cancer, suggesting that celastrol‑mediated autophagy flux inhibition sensitized TRAIL‑initiated apoptosis via regulation of ROS and ΔΨm. |
Pair Name | Casticin, TNF-related apoptosis inducing ligand | |||
Partner Name | Casticin | |||
Disease Info | [ICD-11: 2B72] | Gastric cancer | Investigative | |
Biological Phenomena | Induction-->Endoplasmic reticulum stress | |||
Gene Regulation | Down-regulation | Expression | BCL2 | hsa596 |
Down-regulation | Expression | BCL-xL | hsa598 | |
Down-regulation | Expression | BIRC5 | hsa332 | |
Down-regulation | Expression | CFLAR | hsa8837 | |
Up-regulation | Expression | DDIT3 | hsa1649 | |
Up-regulation | Phosphorylation | EIF2S1 | hsa1965 | |
Up-regulation | Expression | ESR1 | hsa2099 | |
Up-regulation | Expression | HSPA5 | hsa3309 | |
Up-regulation | Expression | ROS1 | hsa6098 | |
Up-regulation | Expression | TNFRSF10B | hsa8795 | |
Down-regulation | Expression | XIAP | hsa331 | |
In Vitro Model | BGC-823 | Human papillomavirus-related cervical adenocarcinoma | Homo sapiens (Human) | CVCL_3360 |
SGC-7901 | Human papillomavirus-related cervical adenocarcinoma | Homo sapiens (Human) | CVCL_0520 | |
MGC-803 | Gastric mucinous adenocarcinoma | Homo sapiens (Human) | CVCL_5334 | |
Result | Casticin enhances TRAIL-induced apoptosis through the downregulation of cell survival proteins and the upregulation of DR5 receptors through actions on the ROS-ER stress-CHOP pathway. |
Pair Name | Capsaicin, TNF-related apoptosis inducing ligand | |||
Partner Name | Capsaicin | |||
Disease Info | [ICD-11: 2A00] | Glioblastoma multiforme | Investigative | |
Biological Phenomena | Induction-->Apoptosis | |||
Gene Regulation | Down-regulation | Expression | BIRC5 | hsa332 |
Down-regulation | Expression | CCNB1 | hsa891 | |
Down-regulation | Expression | POLD1 | hsa5424 | |
Up-regulation | Expression | TNFRSF10B | hsa8795 | |
In Vitro Model | U-87MG ATCC | Glioblastoma | Homo sapiens (Human) | CVCL_0022 |
U-343MG | Glioblastoma | Homo sapiens (Human) | CVCL_S471 | |
T98G | Glioblastoma | Homo sapiens (Human) | CVCL_0556 | |
SNU-444 | Glioblastoma | Homo sapiens (Human) | CVCL_5060 | |
U-251MG | Astrocytoma | Homo sapiens (Human) | CVCL_0021 | |
Result | A combined regimen using capsaicin and TRAIL may provide a safe and effective strategy for treating malignant gliomas. |
Pair Name | Cantharidin, TNF-related apoptosis inducing ligand | |||
Partner Name | Cantharidin | |||
Disease Info | [ICD-11: 2C82] | Prostate cancer | Investigative | |
Biological Phenomena | Induction-->Autophagy | |||
Gene Regulation | Up-regulation | Activity | CASP3 | hsa836 |
Up-regulation | Activity | CASP8 | hsa841 | |
Down-regulation | Expression | CFLAR | hsa8837 | |
Up-regulation | Expression | MAP1LC3B | hsa81631 | |
Up-regulation | Expression | SQSTM1 | hsa8878 | |
Up-regulation | Expression | TNFRSF10B | hsa8795 | |
In Vitro Model | DU145 | Prostate carcinoma | Homo sapiens (Human) | CVCL_0105 |
Result | The results of the present study revealed that cantharidin effectively sensitized cells to TRAIL‑mediated apoptosis and its effects are likely to be mediated by autophagy, the downregulation of c‑FLIP and the upregulation of DR‑5. |
Pair Name | Butein, TNF-related apoptosis inducing ligand | |||
Partner Name | Butein | |||
Disease Info | [ICD-11: 2B33.4] | Leukemia | Investigative | |
Biological Phenomena | Induction-->Apoptosis | |||
Gene Regulation | Up-regulation | Activity | CASP3 | hsa836 |
Up-regulation | Activity | CASP8 | hsa841 | |
Up-regulation | Expression | TNFRSF10A | hsa8797 | |
Up-regulation | Expression | TNFRSF10B | hsa8795 | |
In Vitro Model | U-937 | Adult acute monocytic leukemia | Homo sapiens (Human) | CVCL_0007 |
Result | Our data suggests that combined treatment with butein and TRAIL may provide a safe and effective strategy for treating cancer. |
Pair Name | Bufalin, TNF-related apoptosis inducing ligand | |||
Partner Name | Bufalin | |||
Disease Info | [ICD-11: 2C60] | Breast cancer | Investigative | |
Biological Phenomena | Induction-->Apoptosis | |||
Gene Regulation | Down-regulation | Expression | CBLB | hsa868 |
Up-regulation | Expression | MAPK14 | hsa1432 | |
Up-regulation | Expression | MAPK3 | hsa5595 | |
Up-regulation | Expression | MAPK8 | hsa5599 | |
Up-regulation | Expression | TNFRSF10A | hsa8797 | |
Up-regulation | Expression | TNFRSF10B | hsa8795 | |
In Vitro Model | MCF-7 | Invasive breast carcinoma of no special type | Homo sapiens (Human) | CVCL_0031 |
MDA-MB-231 | Breast adenocarcinoma | Homo sapiens (Human) | CVCL_0062 | |
Result | Bufalin enhanced TRAIL-induced apoptosis by up-regulating the expression of DR4 and DR5. Bufalin-induced down-regulation of Cbl-b contributed to the up-regulation of DR4 and DR5, which might be partially mediated by the activation of ERK, JNK and p38 MAPK. |
Pair Name | Beta-Elemene, TNF-related apoptosis inducing ligand | |||
Partner Name | Beta-Elemene | |||
Disease Info | [ICD-11: 2C25] | Lung cancer | Investigative | |
Biological Phenomena | Induction-->Apoptosis | |||
Gene Regulation | Up-regulation | Expression | CASP3 | hsa836 |
Up-regulation | Expression | CASP8 | hsa841 | |
Up-regulation | Expression | FADD | hsa8772 | |
Up-regulation | Expression | PARP1 | hsa142 | |
Up-regulation | Expression | TNFRSF10B | hsa8795 | |
In Vitro Model | BGC-823 | Human papillomavirus-related cervical adenocarcinoma | Homo sapiens (Human) | CVCL_3360 |
SGC-7901 | Human papillomavirus-related cervical adenocarcinoma | Homo sapiens (Human) | CVCL_0520 | |
Result | Our results suggest that β-elemene increases the sensitivity of gastric cancer cells to TRAIL partially by promoting the formation of DISC in lipid rafts. |
Pair Name | Bakuchiol, TNF-related apoptosis inducing ligand | |||
Partner Name | Bakuchiol | |||
Disease Info | [ICD-11: 2B91] | Colorectal cancer | Investigative | |
Biological Phenomena | Induction-->Apoptosis | |||
Gene Regulation | Down-regulation | Expression | BCL2 | hsa596 |
Down-regulation | Expression | BIRC5 | hsa332 | |
Up-regulation | Cleavage | CASP3 | hsa836 | |
Up-regulation | Cleavage | CASP8 | hsa841 | |
Up-regulation | Cleavage | CASP9 | hsa842 | |
Down-regulation | Expression | CFLAR | hsa8837 | |
Up-regulation | Phosphorylation | MAPK8 | hsa5599 | |
Up-regulation | Cleavage | PARP1 | hsa142 | |
Up-regulation | Expression | TNFRSF10A | hsa8797 | |
Up-regulation | Expression | TNFRSF10B | hsa8795 | |
Down-regulation | Expression | XIAP | hsa331 | |
In Vitro Model | HCT 116 | Colon carcinoma | Homo sapiens (Human) | CVCL_0291 |
HT-29 | Colon adenocarcinoma | Homo sapiens (Human) | CVCL_0320 | |
Result | The collective results suggest that bakuchiol facilitates TRAIL-induced apoptosis in colon cancer cells through up-regulation of the TRAIL receptors; DR4 and DR5 via ROS/JNK pathway signals. |
Pair Name | Artepillin C, TNF-related apoptosis inducing ligand | |||
Partner Name | Artepillin C | |||
Disease Info | [ICD-11: 2C82] | Prostate cancer | Investigative | |
Biological Phenomena | Induction-->Apoptosis | |||
Gene Regulation | Up-regulation | Activity | NFKB1 | hsa4790 |
Up-regulation | Activity | RELA | hsa5970 | |
In Vitro Model | LNCaP | Prostate carcinoma | Homo sapiens (Human) | CVCL_0395 |
Result | The data demonstrate the important role of Brazilian green propolis and its bioactive compounds in prostate cancer chemoprevention through the enhancement of TRAIL-mediated apoptosis. |
Pair Name | Apigenin, TNF-related apoptosis inducing ligand | |||
Partner Name | Apigenin | |||
Disease Info | [ICD-11: 2C12] | Hepatocellular carcinoma | Investigative | |
Biological Phenomena | Induction-->Apoptosis | |||
Gene Regulation | Up-regulation | Expression | TNFRSF10B | hsa8795 |
In Vitro Model | Hep-G2 | Hepatoblastoma | Homo sapiens (Human) | CVCL_0027 |
Result | Sub-toxic dose of apigenin sensitizes HepG2 cells to TRAIL through ERK-dependent up-regulation of TRAIL receptor DR5 |
Pair Name | Apigenin, TNF-related apoptosis inducing ligand | |||
Partner Name | Apigenin | |||
Disease Info | [ICD-11: 2A90] | Anaplastic large cell lymphoma | Investigative | |
Biological Phenomena | Induction-->Apoptosis | |||
Gene Regulation | Down-regulation | Expression | CFLAR | hsa8837 |
Up-regulation | Expression | TNFRSF10B | hsa8795 | |
In Vitro Model | Jurkat | Childhood T acute lymphoblastic leukemia | Homo sapiens (Human) | CVCL_0065 |
SP+ | Healthy | Homo sapiens (Human) | CVCL_1Y11 | |
Result | Apigenin breaks TRAIL resistance in HTLV-1-associated ATL by transcriptional down-regulation of c-FLIP, a key inhibitor of death receptor signaling, and by up-regulation of TRAIL receptor 2 (TRAIL-R2) |
Pair Name | Apigenin, TNF-related apoptosis inducing ligand | |||
Partner Name | Apigenin | |||
Disease Info | [ICD-11: 2C12] | Hepatocellular carcinoma | Investigative | |
Biological Phenomena | Induction-->Apoptosis | |||
Gene Regulation | Up-regulation | Cleavage | CASP3 | hsa836 |
Up-regulation | Cleavage | CASP6 | hsa839 | |
Up-regulation | Cleavage | CASP7 | hsa840 | |
Up-regulation | Cleavage | CASP8 | hsa841 | |
Up-regulation | Cleavage | CASP9 | hsa842 | |
Up-regulation | Cleavage | PARP1 | hsa142 | |
In Vitro Model | Huh-7 | Adult hepatocellular carcinoma | Homo sapiens (Human) | CVCL_0336 |
Result | Apigenin sensitizes cells to TRAIL-induced apoptosis by activating both intrinsic and extrinsic apoptotic pathway-related caspases. The augmented apoptotic effect by TRAIL/apigenin combination was accompanied by triggering mitochondria-dependent signaling pathway, as indicated by Bax/Bcl-2 ratio up-regulation |
Pair Name | Apigenin, TNF-related apoptosis inducing ligand | |||
Partner Name | Apigenin | |||
Disease Info | [ICD-11: 2C25] | Lung cancer | Investigative | |
Biological Phenomena | Induction-->Apoptosis | |||
Gene Regulation | Down-regulation | Expression | AKT1 | hsa207 |
Up-regulation | Expression | BAD | hsa572 | |
Up-regulation | Expression | BAX | hsa581 | |
Down-regulation | Expression | BCL2 | hsa596 | |
Down-regulation | Expression | BCL-xL | hsa598 | |
Down-regulation | Expression | CDH13 | hsa1012 | |
Down-regulation | Expression | MAPK3 | hsa5595 | |
Up-regulation | Expression | TNFRSF10B | hsa8795 | |
In Vitro Model | A-549 | Lung adenocarcinoma | Homo sapiens (Human) | CVCL_0023 |
NCI-H1299 | Lung large cell carcinoma | Homo sapiens (Human) | CVCL_0060 | |
Result | Apigenin enhances TRAIL-induced antitumor activity in NSCLC cells by APG via inhibition of the NF-kappaB, AKT and ERK prosurvival regulators |
Pair Name | Apigenin, TNF-related apoptosis inducing ligand | |||
Partner Name | Apigenin | |||
Disease Info | [ICD-11: 2D10.Z] | Thyroid cancer | Investigative | |
Biological Phenomena | Induction-->Apoptosis | |||
Gene Regulation | Down-regulation | Expression | AKT1 | hsa207 |
Down-regulation | Expression | BCL2 | hsa596 | |
Up-regulation | Phosphorylation | MAPK3 | hsa5595 | |
Up-regulation | Cleavage | PARP1 | hsa142 | |
In Vitro Model | 8505C | Thyroid gland anaplastic carcinoma | Homo sapiens (Human) | CVCL_1054 |
CAL-62 | Thyroid gland anaplastic carcinoma | Homo sapiens (Human) | CVCL_1112 | |
Result | Apigenin synergizes with TRAIL through regulation of Bcl2 family proteins in inducing cytotoxicity, and suppression of AKT potentiates synergistic cytotoxicity of apigenin with TRAIL in ATC cells |
Pair Name | Apigenin, TNF-related apoptosis inducing ligand | |||
Partner Name | Apigenin | |||
Disease Info | [ICD-11: 2C82] | Prostate cancer | Investigative | |
Biological Phenomena | Induction-->Apoptosis | |||
In Vitro Model | LNCaP | Prostate carcinoma | Homo sapiens (Human) | CVCL_0395 |
DU145 | Prostate carcinoma | Homo sapiens (Human) | CVCL_0105 | |
Result | Apigenin markedly augmented TRAIL-mediated apoptosis in prostate cancer cells |
Pair Name | Angelicin, TNF-related apoptosis inducing ligand | |||
Partner Name | Angelicin | |||
Disease Info | [ICD-11: 2C90.Z] | Renal carcinoma | Investigative | |
Biological Phenomena | Induction-->Apoptosis | |||
Gene Regulation | Up-regulation | Activity | CASP3 | hsa836 |
Down-regulation | Expression | CFLAR | hsa8837 | |
In Vitro Model | Caki-1 | Clear cell renal cell carcinoma | Homo sapiens (Human) | CVCL_0234 |
Result | This study provides evidence that angelicin might be a TRAIL sensitizer. |
Pair Name | alpha-Mangostin, TNF-related apoptosis inducing ligand | |||
Partner Name | alpha-Mangostin | |||
Disease Info | [ICD-11: 2B66.0] | Oral squamous cell carcinoma | Investigative | |
Biological Phenomena | Induction-->Blockade of cell cycle in the S/G2/M phase | |||
Gene Regulation | Up-regulation | Activity | CASP3 | hsa836 |
Up-regulation | Activity | CASP7 | hsa840 | |
Up-regulation | Activity | CASP9 | hsa842 | |
Up-regulation | Expression | MYC | hsa4609 | |
In Vitro Model | HSC-4 | Tongue squamous cell carcinoma | Homo sapiens (Human) | CVCL_1289 |
SAS | Tongue squamous cell carcinoma | Homo sapiens (Human) | CVCL_1675 | |
Result | Synergism between α-mangostin and TRAIL induces apoptosis in squamous cell carcinoma of the oral cavity through the mitochondrial pathway |
Pair Name | 20(s)-ginsenoside Rh2, TNF-related apoptosis inducing ligand | |||
Partner Name | 20(s)-ginsenoside Rh2 | |||
Disease Info | [ICD-11: 2C12] | Hepatocellular carcinoma | Investigative | |
Biological Phenomena | Induction-->Apoptosis | |||
Gene Regulation | Down-regulation | Expression | BCL2 | hsa596 |
Down-regulation | Expression | CASP3 | hsa836 | |
Down-regulation | Cleavage | CASP8 | hsa841 | |
Down-regulation | Cleavage | PARP1 | hsa142 | |
Up-regulation | Expression | TNFRSF10B | hsa8795 | |
Down-regulation | Expression | XIAP | hsa331 | |
In Vitro Model | Hep-G2 | Hepatoblastoma | Homo sapiens (Human) | CVCL_0027 |
OV2944-LM-3 | Malignant ovarian neoplasm | Mus musculus (Mouse) | CVCL_E956 | |
L-02 | Human papillomavirus-related cervical adenocarcinoma | Homo sapiens (Human) | CVCL_6926 | |
In Vivo Model | Human hepatocellular carcinoma cells HepG2 (5×10⁵) in the log phase were implanted subcutaneously (s.c.) in the flanks of mice. | |||
Result | Our study indicates that Rh2 may act as a sensitizer in combination with TRAIL to increase the efficacy of its anti-tumor activity. |
Pair Name | Shogaol, TNF-related apoptosis inducing ligand | |||
Partner Name | Shogaol | |||
Disease Info | [ICD-11: 2B90] | Colon cancer | Investigative | |
Biological Phenomena | Induction-->Apoptosis | |||
Gene Regulation | Up-regulation | Expression | BAX | hsa581 |
Down-regulation | Expression | BCL2 | hsa596 | |
Down-regulation | Expression | BIRC5 | hsa332 | |
Up-regulation | Cleavage | CASP3 | hsa836 | |
Up-regulation | Cleavage | CASP8 | hsa841 | |
Up-regulation | Phosphorylation | MAPK1 | hsa5594 | |
Up-regulation | Phosphorylation | MAPK8 | hsa5599 | |
Up-regulation | Cleavage | PARP1 | hsa142 | |
Up-regulation | Expression | TNFRSF10B | hsa8795 | |
In Vitro Model | HCT 116 | Colon carcinoma | Homo sapiens (Human) | CVCL_0291 |
Caco-2 | Colon adenocarcinoma | Homo sapiens (Human) | CVCL_0025 | |
SW620 | Colon adenocarcinoma | Homo sapiens (Human) | CVCL_0547 | |
Result | This study gives rise to the possibility of applying shogaol as an antitumor agent that can be used for the purpose of combination treatment with TRAIL in TRAIL-resistant colon tumor therapy. |
Pair Name | Curcumol, TNF-related apoptosis inducing ligand | |||
Partner Name | Curcumol | |||
Disease Info | [ICD-11: 2C25] | Lung cancer | Investigative | |
Biological Phenomena | Induction-->ROS generation | |||
Gene Regulation | Up-regulation | Cleavage | CASP3 | hsa836 |
Down-regulation | Expression | NQO2 | hsa4835 | |
Up-regulation | Cleavage | PARP1 | hsa142 | |
In Vitro Model | A-549 | Lung adenocarcinoma | Homo sapiens (Human) | CVCL_0023 |
NCI-H1299 | Lung large cell carcinoma | Homo sapiens (Human) | CVCL_0060 | |
NCI-H1975 | Lung adenocarcinoma | Homo sapiens (Human) | CVCL_1511 | |
NCI-H358 | Minimally invasive lung adenocarcinoma | Homo sapiens (Human) | CVCL_1559 | |
NCI-H460 | Lung large cell carcinoma | Homo sapiens (Human) | CVCL_0459 | |
In Vivo Model | BALB/c nude mice (5-week-old) were subcutaneously inoculated with A549 cells (1×10⁶) | |||
Result | This study characterizes the functional role of NQO2 in TRAIL resistance and the sensitizing function of curcumol by directly targeting NQO2, highlighting the potential of using curcumol as an NQO2 inhibitor for clinical treatment of TRAIL-resistant cancers. |
Pair Name | Morusin, TNF-related apoptosis inducing ligand | |||
Partner Name | Morusin | |||
Disease Info | [ICD-11: 2A00] | Glioblastoma multiforme | Investigative | |
Biological Phenomena | Induction-->Apoptosis | |||
Gene Regulation | Down-regulation | Expression | BIRC5 | hsa332 |
Down-regulation | Expression | EGFR | hsa1956 | |
Down-regulation | Phosphorylation | STAT3 | hsa6774 | |
Up-regulation | Expression | TNFRSF10B | hsa8795 | |
Down-regulation | Expression | XIAP | hsa331 | |
In Vitro Model | U-251MG | Astrocytoma | Homo sapiens (Human) | CVCL_0021 |
LN-18 | Glioblastoma | Homo sapiens (Human) | CVCL_0392 | |
Result | These results suggest that morusin enhances TRAIL sensitivity in human glioblastoma cells through regulating expression of DR5 and EGFR. Therefore, the combination treatment of TRAIL and morusin may be a new therapeutic strategy for malignant glioma patients. |
No. | Title | Href |
---|---|---|
1 | Morusin Induces TRAIL Sensitization by Regulating EGFR and DR5 in Human Glioblastoma Cells. J Nat Prod. 2016 Feb 26;79(2):317-23. doi: 10.1021/acs.jnatprod.5b00919. | Click |
2 | Tubeimoside-1 Enhances TRAIL-Induced Apoptotic Cell Death through STAMBPL1-Mediated c-FLIP Downregulation. Int J Mol Sci. 2023 Jul 24;24(14):11840. doi: 10.3390/ijms241411840. | Click |
3 | Thymoquinone Crosstalks with DR5 to Sensitize TRAIL Resistance and Stimulate ROS-Mediated Cancer Apoptosis. Asian Pac J Cancer Prev. 2021 Sep 1;22(9):2855-2865. doi: 10.31557/APJCP.2021.22.9.2855. | Click |
4 | Tanshinone IIA sensitizes TRAIL-induced apoptosis in glioblastoma through inducing the expression of death receptors (and suppressing STAT3 activation). Brain Res. 2021 Sep 1;1766:147515. doi: 10.1016/j.brainres.2021.147515. | Click |
5 | Sulforaphane enhances the therapeutic potential of TRAIL in prostate cancer orthotopic model through regulation of apoptosis, metastasis, and angiogenesis. Clin Cancer Res. 2008 Nov 1;14(21):6855-66. doi: 10.1158/1078-0432.CCR-08-0903. | Click |
6 | Shikonin sensitizes A549 cells to TRAIL-induced apoptosis through the JNK, STAT3 and AKT pathways. BMC Cell Biol. 2018 Dec 29;19(1):29. doi: 10.1186/s12860-018-0179-7. | Click |
7 | Mechanism and therapeutic prospect of resveratrol combined with TRAIL in the treatment of renal cell carcinoma. Cancer Gene Ther. 2020 Aug;27(7-8):619-623. doi: 10.1038/s41417-019-0150-6. | Click |
8 | Pterostilbene Enhances TRAIL-Induced Apoptosis through the Induction of Death Receptors and Downregulation of Cell Survival Proteins in TRAIL-Resistance Triple Negative Breast Cancer Cells. J Agric Food Chem. 2017 Dec 27;65(51):11179-11191. doi: 10.1021/acs.jafc.7b02358. | Click |
9 | Combination of the natural compound Periplocin and TRAIL induce esophageal squamous cell carcinoma apoptosis in vitro and in vivo: Implication in anticancer therapy. J Exp Clin Cancer Res. 2019 Dec 21;38(1):501. doi: 10.1186/s13046-019-1498-z. | Click |
10 | Antitumor Effect of Periplocin in TRAIL-Resistant gastric cancer cells via upregulation of death receptor through activating ERK1/2-EGR1 pathway. Mol Carcinog. 2019 Jun;58(6):1033-1045. doi: 10.1002/mc.22991. | Click |
11 | Neobavaisoflavone sensitizes apoptosis via the inhibition of metastasis in TRAIL-resistant human glioma U373MG cells. Life Sci. 2014 Jan 30;95(2):101-7. doi: 10.1016/j.lfs.2013.10.035. | Click |
12 | Medicarpin, a legume phytoalexin sensitizes myeloid leukemia cells to TRAIL-induced apoptosis through the induction of DR5 and activation of the ROS-JNK-CHOP pathway. Cell Death Dis. 2014 Oct 16;5(10):e1465. doi: 10.1038/cddis.2014.429. | Click |
13 | Luteolin enhances TRAIL sensitivity in non-small cell lung cancer cells through increasing DR5 expression and Drp1-mediated mitochondrial fission. Arch Biochem Biophys. 2020 Oct 15;692:108539. doi: 10.1016/j.abb.2020.108539. | Click |
14 | Luteolin enhances TNF-related apoptosis-inducing ligand's anticancer activity in a lung cancer xenograft mouse model. Biochem Biophys Res Commun. 2012 Jan 13;417(2):842-6. doi: 10.1016/j.bbrc.2011.12.055. | Click |
15 | Luteolin-regulated MicroRNA-301-3p Targets Caspase-8 and Modulates TRAIL Sensitivity in PANC-1 Cells. Anticancer Res. 2020 Feb;40(2):723-731. doi: 10.21873/anticanres.14003. | Click |
16 | Combining TRAIL and liquiritin exerts synergistic effects against human gastric cancer cells and xenograft in nude mice through potentiating apoptosis and ROS generation. Biomed Pharmacother. 2017 Sep;93:948-960. doi: 10.1016/j.biopha.2017.06.095. | Click |
17 | Licochalcone B induces DNA damage, cell cycle arrest, apoptosis, and enhances TRAIL sensitivity in hepatocellular carcinoma cells. Chem Biol Interact. 2022 Sep 25;365:110076. doi: 10.1016/j.cbi.2022.110076. | Click |
18 | Kurarinone Synergizes TRAIL-Induced Apoptosis in Gastric Cancer Cells. Cell Biochem Biophys. 2015 May;72(1):241-9. doi: 10.1007/s12013-014-0444-0. | Click |
19 | Kaempferol sensitizes colon cancer cells to TRAIL-induced apoptosis. Biochem Biophys Res Commun. 2008 Oct 10;375(1):129-33. doi: 10.1016/j.bbrc.2008.07.131. | Click |
20 | Kaempferol sensitizes tumor necrosis factor-related apoptosis-inducing ligand-resistance chronic myelogenous leukemia cells to apoptosis. Mol Biol Rep. 2022 Jan;49(1):19-29. doi: 10.1007/s11033-021-06778-z. | Click |
21 | Effects of A.marina-Derived Isoquercitrin on TNF-Related Apoptosis-Inducing Ligand Receptor (TRAIL-R) Expression and Apoptosis Induction in Cervical Cancer Cells. Appl Biochem Biotechnol. 2017 Jun;182(2):697-707. doi: 10.1007/s12010-016-2355-6. | Click |
22 | Combination of isoliquiritigenin and tumor necrosis factor-related apoptosis-inducing ligand induces apoptosis in colon cancer HT29 cells. Environ Health Prev Med. 2008 Sep;13(5):281-7. doi: 10.1007/s12199-008-0041-1. | Click |
23 | Irigenin sensitizes TRAIL-induced apoptosis via enhancing pro-apoptotic molecules in gastric cancer cells. Biochem Biophys Res Commun. 2018 Feb 12;496(3):998-1005. doi: 10.1016/j.bbrc.2018.01.003. | Click |
24 | Icaritin Sensitizes Human Glioblastoma Cells to TRAIL-Induced Apoptosis. Cell Biochem Biophys. 2015 Jun;72(2):533-42. doi: 10.1007/s12013-014-0499-y. | Click |
25 | Gomisin N enhances TRAIL-induced apoptosis via reactive oxygen species-mediated up-regulation of death receptors 4 and 5. Int J Oncol. 2012 Apr;40(4):1058-65. doi: 10.3892/ijo.2011.1299. | Click |
26 | Gambogic acid sensitizes breast cancer cells to TRAIL-induced apoptosis by promoting the crosstalk of extrinsic and intrinsic apoptotic signalings. Food Chem Toxicol. 2018 Sep;119:334-341. doi: 10.1016/j.fct.2018.02.037. | Click |
27 | Sensitization of TRAIL-resistant cervical cancer cells through combination of TRAIL and fucoxanthin treatments. Eur Rev Med Pharmacol Sci. 2017 Dec;21(24):5594-5601. doi: 10.26355/eurrev_201712_14000. | Click |
28 | Fucoxanthin and Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand (TRAIL) Synergistically Promotes Apoptosis of Human Cervical Cancer Cells by Targeting PI3K/Akt/NF-κB Signaling Pathway. Med Sci Monit. 2018 Jan 1;24:11-18. doi: 10.12659/msm.905360. | Click |
29 | Activation of autophagic flux by epigallocatechin gallate mitigates TRAIL-induced tumor cell apoptosis via down-regulation of death receptors. Oncotarget. 2016 Oct 4;7(40):65660-65668. doi: 10.18632/oncotarget.11597. | Click |
30 | Epigalocatechin-3-gallate (EGCG) downregulates PEA15 and thereby augments TRAIL-mediated apoptosis in malignant glioma. Neurosci Lett. 2008 Dec 19;448(1):161-5. doi: 10.1016/j.neulet.2008.10.036. | Click |
31 | EGCG enhances TRAIL-mediated apoptosis in human melanoma A375 cell line. J Huazhong Univ Sci Technolog Med Sci. 2009 Dec;29(6):771-5. doi: 10.1007/s11596-009-0620-4. | Click |
32 | Combinatorial effect of epigallocatechin-3-gallate and TRAIL on pancreatic cancer cell death. Int J Oncol. 2009 Jan;34(1):281-6. | Click |
33 | EGCG sensitizes human nasopharyngeal carcinoma cells to TRAIL-mediated apoptosis by activation NF-κB. Neoplasma. 2017;64(1):74-80. doi: 10.4149/neo_2017_109. | Click |
34 | Green tea polyphenol EGCG sensitizes human prostate carcinoma LNCaP cells to TRAIL-mediated apoptosis and synergistically inhibits biomarkers associated with angiogenesis and metastasis. Oncogene. 2008 Mar 27;27(14):2055-63. doi: 10.1038/sj.onc.1210840. | Click |
35 | Decursin enhances TRAIL-induced apoptosis through oxidative stress mediated- endoplasmic reticulum stress signalling in non-small cell lung cancers. Br J Pharmacol. 2016 Mar;173(6):1033-44. doi: 10.1111/bph.13408. | Click |
36 | Potentiation of TRAIL-Induced Apoptosis in TRAIL-Resistant Cholangiocarcinoma Cells by Curcumin through the Induction of DR5 Membrane Localization and Disruption of the Anti-Apoptotic Complex DR5/DDX3/GSK3β. Asian Pac J Cancer Prev. 2023 Feb 1;24(2):425-434. doi: 10.31557/APJCP.2023.24.2.425. | Click |
37 | Curcumin sensitizes human lung cancer cells to apoptosis and metastasis synergistically combined with carboplatin. Exp Biol Med (Maywood). 2015 Nov;240(11):1416-25. doi: 10.1177/1535370215571881. | Click |
38 | Novel TRAIL sensitizer Taraxacum officinale F.H. Wigg enhances TRAIL-induced apoptosis in Huh7 cells. Mol Carcinog. 2016;55(4):387-396. doi:10.1002/mc.22288 | Click |
39 | Celastrol enhances TRAIL-induced apoptosis in human glioblastoma via the death receptor pathwayCelastrol enhances TRAIL-induced apoptosis in human glioblastoma via the death receptor pathway. Cancer Chemother Pharmacol. 2019 Oct;84(4):719-728. doi: 10.1007/s00280-019-03900-8. | Click |
40 | Autophagy flux inhibition mediated by celastrol sensitized lung cancer cells to TRAIL‑induced apoptosis via regulation of mitochondrial transmembrane potential and reactive oxygen species. Mol Med Rep. 2019 Feb;19(2):984-993. doi: 10.3892/mmr.2018.9757. | Click |
41 | Casticin potentiates TRAIL-induced apoptosis of gastric cancer cells through endoplasmic reticulum stress. PLoS One. 2013;8(3):e58855. doi: 10.1371/journal.pone.0058855. | Click |
42 | Capsaicin sensitizes malignant glioma cells to TRAIL-mediated apoptosis via DR5 upregulation and survivin downregulation. Carcinogenesis. 2010 Mar;31(3):367-75. doi: 10.1093/carcin/bgp298. | Click |
43 | Downregulation of c‑FLIP and upregulation of DR‑5 by cantharidin sensitizes TRAIL‑mediated apoptosis in prostate cancer cells via autophagy flux. Int J Mol Med. 2020 Jul;46(1):280-288. doi: 10.3892/ijmm.2020.4566. | Click |
44 | Butein sensitizes human leukemia cells to apoptosis induced by tumor necrosis factor-related apoptosis inducing ligand (TRAIL). Arch Pharm Res. 2008 Sep;31(9):1179-86. doi: 10.1007/s12272-001-1286-2. | Click |
45 | Down-regulation of Cbl-b by bufalin results in up-regulation of DR4/DR5 and sensitization of TRAIL-induced apoptosis in breast cancer cells. J Cancer Res Clin Oncol. 2012 Aug;138(8):1279-89. doi: 10.1007/s00432-012-1204-4. | Click |
46 | β-elemene increases the sensitivity of gastric cancer cells to TRAIL by promoting the formation of DISC in lipid rafts. Cell Biol Int. 2018 Sep;42(10):1377-1385. doi: 10.1002/cbin.11023. | Click |
47 | Bakuchiol sensitizes cancer cells to TRAIL through ROS- and JNK-mediated upregulation of death receptors and downregulation of survival proteins. Biochem Biophys Res Commun. 2016 Apr 29;473(2):586-92. doi: 10.1016/j.bbrc.2016.03.127. | Click |
48 | Ethanolic extract of Brazilian green propolis sensitizes prostate cancer cells to TRAIL-induced apoptosis. Int J Oncol. 2011 Apr;38(4):941-53. doi: 10.3892/ijo.2011.930. | Click |
49 | Sub-toxic dose of apigenin sensitizes HepG2 cells to TRAIL through ERK-dependent up-regulation of TRAIL receptor DR5. Mol Cells. 2013 Jan;35(1):32-40. doi: 10.1007/s10059-013-2175-2. | Click |
50 | Wogonin and related natural flavones overcome tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) protein resistance of tumors by down-regulation of c-FLIP protein and up-regulation of TRAIL receptor 2 expression. J Biol Chem. 2012 Jan 2;287(1):641-649. doi: 10.1074/jbc.M111.286526. | Click |
51 | Apigenin Sensitizes Huh-7 Human Hepatocellular Carcinoma Cells to TRAIL-induced Apoptosis. Biomol Ther (Seoul). 2012 Jan;20(1):62-7. doi: 10.4062/biomolther.2012.20.1.062. | Click |
52 | Apigenin potentiates TRAIL therapy of non-small cell lung cancer via upregulating DR4/DR5 expression in a p53-dependent manner. Sci Rep. 2016 Oct 18;6:35468. doi: 10.1038/srep35468. | Click |
53 | Suppression of AKT Potentiates Synergistic Cytotoxicity of Apigenin with TRAIL in Anaplastic Thyroid Carcinoma Cells. Anticancer Res. 2015 Dec;35(12):6529-37. | Click |
54 | Ethanolic Extract of Propolis Augments TRAIL-Induced Apoptotic Death in Prostate Cancer Cells. Evid Based Complement Alternat Med. 2011;2011:535172. doi: 10.1093/ecam/nep180. | Click |
55 | Angelicin potentiates TRAIL-induced apoptosis in renal carcinoma Caki cells through activation of caspase 3 and down-regulation of c-FLIP expression. Drug Dev Res. 2018 Feb;79(1):3-10. doi: 10.1002/ddr.21414. | Click |
56 | Synergism between α-mangostin and TRAIL induces apoptosis in squamous cell carcinoma of the oral cavity through the mitochondrial pathway. Oncol Rep. 2017 Dec;38(6):3439-3446. doi: 10.3892/or.2017.6030. | Click |
57 | 20(s)-ginsenoside Rh2 promotes TRAIL-induced apoptosis by upregulating DR5 in human hepatocellular carcinoma cells. Med Oncol. 2022 May 15;39(5):70. doi: 10.1007/s12032-022-01663-6. | Click |
58 | Shogaol overcomes TRAIL resistance in colon cancer cells via inhibiting of survivin. Tumour Biol. 2015 Nov;36(11):8819-29. doi: 10.1007/s13277-015-3629-2. | Click |
59 | Curcumol Overcomes TRAIL Resistance of Non-Small Cell Lung Cancer by Targeting NRH:Quinone Oxidoreductase 2 (NQO2). Adv Sci (Weinh). 2020 Oct 15;7(22):2002306. doi: 10.1002/advs.202002306. | Click |